Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -47981.26% is in line with its 5-year average of -48775.41%, near the high end of its 5-year range (-227823.29%–0.00%).
66.03% above its 12-month average of -141247.51%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2026 (2026-03-31): -48607.43%.
EBITDA MARGIN
-47981.26%
EBITDA MARGIN AVG TTM
-141247.51%
EBITDA MARGIN AVG 3Y
-69679.15%
EBITDA MARGIN AVG 5Y
-48775.41%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+66.03%
CURRENT VS 3Y AVG
+31.14%
CURRENT VS 5Y AVG
+1.63%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Virax Biolabs Group Limited
Market Cap
$378849.00
EBITDA Margin
-47981.26%
TTM Avg
-141247.51%
3Y Avg
-69679.15%
5Y Avg
-48775.41%
Market Cap
$403887.00
EBITDA Margin
-2196.68%
TTM Avg
-1727.24%
3Y Avg
-1664.72%
5Y Avg
-2055.32%
Market Cap
$250443.00
EBITDA Margin
-994.74%
TTM Avg
-759.01%
3Y Avg
-558.46%
5Y Avg
-556.54%
Market Cap
$518606.00
EBITDA Margin
-8567.94%
TTM Avg
-8572.17%
3Y Avg
-8860.20%
5Y Avg
-7239.32%
Market Cap
$545796.00
EBITDA Margin
-18836.70%
TTM Avg
-9969.53%
3Y Avg
-5254.43%
5Y Avg
-4229.16%
Market Cap
$110112.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$667469.00
EBITDA Margin
-650.71%
TTM Avg
-399.98%
3Y Avg
-297.88%
5Y Avg
-236.24%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Virax Biolabs Group Limited (VRAX) | $378849.00 | -47981.26% | -141247.51% | -69679.15% | -48775.41% |
| Niki BioSolutions, Inc. (NIKI)vs › | $403887.00 | -2196.68% | -1727.24% | -1664.72% | -2055.32% |
| XORTX Therapeutics Inc. (XRTX)vs › | $481786.00 | N/A | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | -994.74% | -759.01% | -558.46% | -556.54% |
| VivoSim Labs, Inc. (VIVS)vs › | $518606.00 | -8567.94% | -8572.17% | -8860.20% | -7239.32% |
| HCW Biologics Inc. (HCWB)vs › | $545796.00 | -18836.70% | -9969.53% | -5254.43% | -4229.16% |
| Silexion Therapeutics Ltd. (SLXN)vs › | $110112.00 | N/A | N/A | N/A | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $667469.00 | -650.71% | -399.98% | -297.88% | -236.24% |
| Psyence Biomedical Ltd. (PBM)vs › | $95475.00 | N/A | N/A | N/A | N/A |
| PRF Technologies Ltd. (PRFX)vs › | $70884.00 | -24782.35% | -24782.35% | -17538.85% | -17538.85% |
Gross Margin
61.9%
EBITDA Margin
-47981.3%
Operating Margin
-51515.2%
Net Margin
-40439.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -48607.43% |
| 2025-09-30 | -147311.82% |
| 2025-03-31 | -227823.29% |
| 2024-09-30 | -55861.18% |
| 2024-03-31 | -4635.78% |
| 2023-09-30 | -3514.38% |
| 2023-03-31 | -0.18% |
| 2022-09-30 | -0.07% |
| 2022-03-31 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-09-30 | -0.01% |
| 2020-03-31 | -620.52% |
| 2019-09-30 | 206.84% |
